CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

GlobeNewswire Pharma
Original article

Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth

EarningsXDEMVYPositive
AI Analysis

Summary

Tarsus Pharmaceuticals reported Q2 2026 XDEMVY net product sales of $173.9 million, representing a 69% year-over-year increase, while advancing its next growth phase.

Financial Highlights

Revenue

$173.9 million

Importance:5/10
Sentiment:
0.70
earningsQ2 2026revenue growthXDEMVY
Related Companies

Read the original article

Published by GlobeNewswire Pharma on August 6, 2026 11:03 AM

Read Original